NCT03601975Unknown3 期
Phase III Randomized Trial of Anlotinib Plus Gemcitabine/Cisplatin Vesus Placebo Plus Gemcitabine/Cisplatin in Previous Untreated Patients With Recurrent/Metastatic Nasopharyngeal Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 入组人数
- 336
- 试验地点
- 1
- 主要终点
- PFS
研究概览
简要总结
This is a Phase III randomized controlled multi-center trial comparing anlotinib plus Gemcitabine/Cisplatin with placebo plus Gemcitabine/Cisplatin in previous untreated patients with recurrent/metastatic Nasopharyngeal Carcinoma, in order to verify the efficacy and security of anlotinib in mNPC patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Single (Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Informed of the investigational nature of this study and give written informed consent
- •Histologically or cytologically confirmed nasopharyngeal carcinoma, tumor staged as IVB (according to the 8th AJCC edition) or recurrent tumor nott suitable for local treatment.
- •Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 to1, life expectancy of at least 12 weeks.
- •Antitumor therapy naive for recurrent or metastatic nasopharyngeal carcinoma
- •Completed radiotherapy for local tumor 4 weeks before the enrollment
- •Measurable disease other than brain metastasis based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
- •Adequate organ system function, defined as follows:
- •ANC ≥1.5×109/L, PLT ≥100×109/L, Hb）≥90g /L;
- •TBIL ≤ 1.5×ULN；Aminopherases (ALT and AST) ≤ 2.5 × ULN (without liver metastasis) or ≤ 5.0 × ULN (with liver metastasis), Creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 ml/min;
- •Urine protein < ++，or urine protein ≥ ++ concomitant with content of -hour urinary protein <1.0 g;
- •INR≤1.5×ULN, APTT≤1.5×ULN;
- •Women who are not of child-bearing potential, and women of child-bearing potential who have a negative serum or urine pregnancy test prior to initial trial treatment, and who agree to use adequate contraceptive measures during the study; Men with partners of childbearing potential willing to use adequate contraceptive measures during the study
排除标准
- •Patients with a previous malignancy within the past 5 years (other than curatively treated in situ carcinoma of the cervix, non-melanoma skin cancer and superficial bladder carcinoma).
- •Allergic to anotinib or the chemotherapeutic agents involved in this trial;
- •Supposed to receive locally treatment (except for those with symptomatic bone metastases receive appropriate local doses radiotherapy which does not affect the hemogram)
- •Patients that have received definitive radiotherapy, adjuvant chemotherapy or cocurrent chemoradiotherapy for stage I-IVA and developed recurrent disease within 6 months;
- •Patients that have previously received target therapies;
- •Patients that have previously received immunotherapy (i.e.,interferon, or IL-2 ) 28 days before randomization or within 5 half-life of the drug.
- •Patients that have previously received immunosupressive drugs (i.e., Corticosteroids, cyclophosphamide, azathioprine, methotrexate, thalidomide or TNF-α)
- •Symptomatic CNS metastasis (i.e. encephaledema, hormone intervention, or brain metastasis progression)
- •Patients currently have bleeding tendency, including but not limited to gastrointestinal bleeding, nasal bleeding, hemoptysis, and persistent bleeding or coagulopathy;
- •Hemoptysis (defined as coughing out or spitting out ≥ 1 teaspoon of blood or small blood clots or hemoptysis without sputum) within 28 days before randomization, not including bloody sputum.
- •Radiograph (within 28 days before randomization) showed that the tumor surrounded important blood vessels, and the investigators determined that entering the study would cause bleeding risk;
- •Subjects have any of the following severe acute complications:
- •Unstable angina and/or congestive heart failure or vascular disease (eg, aortic aneurysm requires surgically repaired or peripheral venous thromboembolism) requiring hospitalization within 12 months, or other cardiac impairments (eg,uncontrolled arrhythmias) determined by the investigator, which may affect the evaluation of drug safety; Myocardial infarction or ischemia with ST elevation ≥ 2 mm indicated by ECG;
- •Arterial thromboembolism, venous thromboembolism in grade 3 or higher (according to NCI-CTCAE), transient ischemic attack (TIA), cerebral vascular accident (CVA), transmural myocardial infarction ( MI), hypertensive crisis or hypertensive encephalopathy within 24weeks;
- •Chronic Obstructive Pulmonary Disease (COPD) or other respiratory diseases requiring hospitalization within 28 days before randomization;
- •Abdominal fistula, gastrointestinal perforation, intra-abdominal abscess, or acute gastrointestinal bleeding within 24 weeks before randomization;
- •Esophageal and gastric varices, unhealed ulcers, unhealed wounds or fracture within 24 weeks before randomization;
- •Pulmonary infections and/or acute bacterial or fungal infections requiring intravenous antibiotic therapy
- •Clinical jaundice and/or coagulation disorders caused by liver dysfunction;
- •Minor surgical procedures (including catheterization, excluding peripheral venipuncture central vena catheterization) within 2 days of randomization;
- •The virological test indicates that either of the following 28 days before randomization
- •HBsAg positive and HBV DNA ≥ 1 × 103 copies/L;
- •Anti-HCV positive
- •HIV positive
- •Participation of an anti-tumor clinic trial within 28 days before randomization
研究组 & 干预措施
anlotinib plus Gemcitabine/Cisplatin
Experimental
patients receive anlotinib at 12mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
干预措施: Gemcitabine/Cisplatin (Drug)
placebo plus Gemcitabine/Cisplatin
Placebo Comparator
patients receive pacebo at 0mg QD (d1-d14)and gemcitabine (1000 mg/m² d1,8) or cisplatin (80mg/m² d1) every 3 weeks for every cycle
干预措施: Gemcitabine/Cisplatin (Drug)
结局指标
主要结局
PFS
时间窗: 12months
Progeression free survival is calculated from randomization to disease progeression or death
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Trial Comparing Adjuvant Chemotherapy With Gemcitabine Versus mFolfirinox to Treat Resected Pancreatic AdenocarcinomaPancreatic Adenocarcinoma (Ductal Adenocarcinoma)NCT01526135UNICANCER493
已完成
3 期
Gemcitabine With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic CancerAdenocarcinoma of the PancreasRecurrent Pancreatic CancerStage II Pancreatic CancerStage III Pancreatic CancerStage IV Pancreatic CancerNCT00088894National Cancer Institute (NCI)590
进行中（未招募）
3 期
Adjuvant Chemotherapy with Gemcitabine and Cisplatin Compared to Standard of Care After Curative Intent Resection of Biliary Tract CancerGall Bladder CarcinomaCholangiocarcinomaNCT02170090Universitätsklinikum Hamburg-Eppendorf789
已完成
3 期
Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed by the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed by SurgeryPancreatic AdenocarcinomaPancreatic Ductal AdenocarcinomaPancreatic Intraductal Papillary-Mucinous NeoplasmStage I Pancreatic Cancer AJCC v6 and v7Stage II Pancreatic Cancer AJCC v6 and v7NCT01013649National Cancer Institute (NCI)546
已完成
3 期
Gemcitabine Hydrochloride and Cisplatin With or Without Nab-Paclitaxel in Treating Patients With Newly Diagnosed Advanced Biliary Tract CancersStage III Distal Bile Duct Cancer AJCC v8Stage III Gallbladder Cancer AJCC v8Stage III Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIA Distal Bile Duct Cancer AJCC v8Stage IIIA Gallbladder Cancer AJCC v8Stage IIIA Intrahepatic Cholangiocarcinoma AJCC v8Stage IIIB Distal Bile Duct Cancer AJCC v8Stage IIIB Gallbladder Cancer AJCC v8Stage IIIB Intrahepatic Cholangiocarcinoma AJCC v8Stage IV Distal Bile Duct Cancer AJCC v8Stage IV Gallbladder Cancer AJCC v8Stage IV Intrahepatic Cholangiocarcinoma AJCC v8Stage IVA Gallbladder Cancer AJCC v8Stage IVB Gallbladder Cancer AJCC v8Unresectable Extrahepatic Bile Duct CarcinomaUnresectable Gallbladder CarcinomaUnresectable Intrahepatic CholangiocarcinomaNCT03768414SWOG Cancer Research Network452